ProQR Therapeutics

ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

RalphLauren.Shutterstock

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

BZAI

CART

PRQR

This Ralph Lauren Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Nvidia Corporation (NVDA)

Movers

AMAT

AMGN

CMPO

LAZR

LUNR

NGNE

NVDA

OMER

RZLV

Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Stock market analysts

Upgrades

FSLR

This First Solar Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

ProQR Therapeutics N.V. - Ordinary Shares

ProQR Therapeutics NV

Press Releases

ProQR Announces Second Quarter 2024 Operating and Financial Results

ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

ProQR Announces Third Quarter 2024 Operating and Financial Results

ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024

ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration

Comments

ProQR Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga